OvaScience Inc. (OVAS)

0.98
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 0.98
Open 0.98
Day Low/High 0.96 / 0.99
52 Wk Low/High 0.71 / 1.96
Volume 76.56K
Avg Volume 407.90K
Exchange NASDAQ
Shares Outstanding 35.66M
Market Cap 34.95M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

OvaScience SM, Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an...

OvaScience To Host Fourth Quarter And Fiscal Year 2017 Financial Results Conference Call

OvaScience To Host Fourth Quarter And Fiscal Year 2017 Financial Results Conference Call

OvaScience¿ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that it will host a...

OVASCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In OvaScience, Inc. To Contact The Firm

OVASCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In OvaScience, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OvaScience, Inc.

OVASCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In OvaScience, Inc. To Contact The Firm

OVASCIENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In OvaScience, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OvaScience, Inc.

OvaScience To Present At The 36th Annual J.P. Morgan Healthcare Conference

OvaScience To Present At The 36th Annual J.P. Morgan Healthcare Conference

OvaScience¿ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that Christopher Kroeger,...

OvaScienceSM Announces Corporate Update

OvaScienceSM Announces Corporate Update

OvaScience (NASDAQ:OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today provided a corporate update.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Claims Against OvaScience, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Claims Against OvaScience, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential claims on behalf of shareholders of OvaScience, Inc.

Scott+Scott, Attorneys At Law, LLP Files Federal Class Action Against OvaScience, Inc.

Scott+Scott, Attorneys At Law, LLP Files Federal Class Action Against OvaScience, Inc.

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, today announced that it has filed a class action against OvaScience, Inc.

OvaScience Reports Third Quarter 2017 Financial Results

OvaScience Reports Third Quarter 2017 Financial Results

OvaScience¿ (NASDAQ:OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options for women, today reported financial results and provided a business update for the...

OvaScience To Host Third Quarter 2017 Financial Results Conference Call

OvaScience To Host Third Quarter 2017 Financial Results Conference Call

OvaScience SM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.

OvaScience Reports Second Quarter 2017 Financial Results

OvaScience Reports Second Quarter 2017 Financial Results

OvaScience SM (NASDAQ:OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the second quarter...

OvaScience To Host Second Quarter 2017 Financial Results Conference Call

OvaScience To Host Second Quarter 2017 Financial Results Conference Call

OvaScience SM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.

OvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

OvaScience¿, Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly...

OvaScience Appoints Christopher Kroeger, M.D., M.B.A., As Chief Executive Officer

OvaScience¿, Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the appointment of Christopher Kroeger, M.

OvaScience Completes Enrollment Of 70 Patients In OvaPrime Clinical Study In Women With Primary Ovarian Insufficiency Or Poor Ovarian Response

OvaScience SM Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced it has completed enrollment of 70 patients in its ongoing...

OvaScience Reports First Quarter 2017 Financial Results

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the first...

OvaScience To Host First Quarter 2017 Financial Results Conference Call

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In OvaScience, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of...

OvaScience Stock Sees Short Interest Expand By 29.7%

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 1,457,802 share increase in total short interest for OvaScience Inc. , to 6,361,911, an increase of 29.73% since 03/31/2017.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In OvaScience, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of...

OvaScience Reports Fourth Quarter And Year-End 2016 Financial Results

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the fourth...

OvaScience To Present At Upcoming Investor Conferences In March

OvaScience¿ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Christophe Couturier, Chief Financial Officer of...

OvaScience To Host Fourth Quarter And Fiscal Year 2016 Financial Results Conference Call

OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Newman Ferrara LLP Announces Corporate Governance Investigation Of OvaScience, Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of OvaScience, Inc.

OvaScience Stock Sees Short Interest Move 10.4% Higher

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 492,925 share increase in total short interest for OvaScience Inc. , to 5,232,302, an increase of 10.40% since 01/13/2017.

TheStreet Quant Rating: D- (Sell)